Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
11/2004
11/03/2004EP1472255A1 Aza-arylpiperazines
11/03/2004EP1472227A2 Process for the manufacture of organic compounds
11/03/2004EP1296968B1 Method for the production of propylene oxide
11/03/2004EP1206452B1 Novel method for preparing benzoperhydroisoindole compounds
11/03/2004CN1543464A Novel imidazopyridine compounds with therapeutic effect
11/03/2004CN1543462A Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
11/03/2004CN1542002A Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation
11/03/2004CN1173974C Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist
11/03/2004CN1173970C Tetrahydroquinoline derivatives as glycine antagonists
11/03/2004CN1173953C Method for preparing 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
11/02/2004CA2320676C Process and intermediates for the preparation of aminotriazine derivatives
10/2004
10/28/2004WO2004092125A2 Using alkylmetal reagents for directed metalation of azaaromatics
10/28/2004WO2004092124A2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
10/28/2004WO2004092123A2 Inhibitors of fungal invasion
10/28/2004WO2004092121A2 Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
10/28/2004WO2004092120A2 Pyrimidinone compounds as calcilytics
10/28/2004WO2004092119A2 Method for producing alpha-methylated cysteine and serine derivatives
10/28/2004WO2004072030A3 Process for preparing pyrrolotriazine kinase inhibitors
10/28/2004WO2004048328A3 N-arylsulfonyl-3-aminoalkoxyindoles
10/28/2004US20040215400 Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel KcsA
10/28/2004US20040215025 formation of by-products by polymerisation of the alkylating agent is avoided whereby a reduction in the amount of alkylating reagent to be used is made possible; high yields
10/28/2004US20040214843 Such as spiro(cyclohexane-1-4'-(3',4'-dihydro)quinazolin)-2'(1'H)-one for treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, asthma and cancer
10/28/2004US20040214841 Quinazoline derivatives for treatment of tumours
10/28/2004US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
10/28/2004US20040214814 Pyrazole compounds useful as protein kinase inhibitors
10/28/2004US20040214808 administering to treat thromboembolic disorders; cardiovascular disorders
10/28/2004US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist
10/28/2004CA2521383A1 Using alkylmetal reagents for directed metalation of azaaromatics
10/28/2004CA2521129A1 Pyrimidinone compounds as calcilytics
10/27/2004EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
10/27/2004EP1470109A1 Metabolites of (3- [(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl -phenoxy)-acetic acid
10/27/2004EP1089984B1 Non-yellowing para-tertiary-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers
10/27/2004EP0970073B1 Process for preparing eprosartan
10/27/2004CN1541215A HIV inhibiting pyrimidines derivatives
10/27/2004CN1539825A Compounds useful to treat retroviral infections
10/21/2004WO2004089940A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004WO2004089890A2 Process and intermediates for preparing benzazepines
10/21/2004WO2004089312A2 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209922 Pyridine matrix metalloproteinase inhibitors
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents
10/21/2004CA2522023A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004CA2517833A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/20/2004EP1468689A1 2-methyl-thieno-benzodiazepine formulation
10/20/2004EP1468687A1 Compounds for the treatment of cancer
10/20/2004EP1468686A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
10/20/2004EP1467800A1 Device for mini-invasive ultrasound treatment of an object by a heat-isolated transducer
10/20/2004EP1467731A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
10/20/2004EP1230236B1 Compound with growth hormone releasing properties
10/20/2004EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones
10/20/2004EP1149074B1 Acetylenic sulfonamide thiol tace inhibitors
10/20/2004EP1140941B1 Nitrogen containing heterobicycles as factor xa inhibitors
10/20/2004EP0862555B1 Substituted aryl or heteroarylamides having retinoid-like biological activity
10/20/2004CN1171861C Halogenated amidino amino acid dervatives useful as nitric oxide synthase inhibitors
10/14/2004WO2004087704A1 Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
10/14/2004WO2004087686A2 Benzopyran compounds useful for treating inflammatory conditions
10/14/2004WO2004087658A1 Indolone-acetamide derivatives, processes for preparing them and their uses
10/14/2004WO2004087654A2 Phospholipase c inhibitors for use in treating inflammatory disorders
10/14/2004WO2004087652A2 Imidazotriazine compounds
10/14/2004WO2004087651A2 Formulations for tyrosine kinase inhibitors
10/14/2004WO2004087650A2 Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
10/14/2004WO2004087649A2 Benodiazepine spirohydantoin cgrp receptor antagonists
10/14/2004WO2004087648A2 Stabilized phenytoin containing composition
10/14/2004WO2004087646A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
10/14/2004WO2004078116A3 P38 inhibitors and methods of use thereof
10/14/2004WO2004076414A3 Novel compounds
10/14/2004WO2004067508A3 Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
10/14/2004WO2004058700A3 Mitotic kinesin inhibitors
10/14/2004CA2520724A1 Benzopyran compounds useful for treating inflammatory conditions
10/14/2004CA2520568A1 Indolone-acetamide derivatives, processes for preparing them and their uses
10/14/2004CA2519515A1 Benodiazepine spirohydantoin cgrp receptor antagonists
10/14/2004CA2519106A1 Formulations for tyrosine kinase inhibitors
10/13/2004EP1465898A1 Biocidal compounds and their preparation
10/13/2004EP1465893A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo (3.2.1) octane, the preparation thereof and the application of same in therapeutics
10/13/2004EP1465864A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
10/13/2004CN1537112A Pyrimidine compound
10/13/2004CN1537101A Pyridine matrix metalloproteinase inhibitors
10/13/2004CN1537098A Crystalline forms VI and VII of atorvastatin calcium
10/07/2004WO2004085388A2 Cyclic protein tyrosine kinase inhibitors
10/07/2004WO2004054514A3 C-6 modified indazolylpyrrolotriazines
10/07/2004WO2004011426A3 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
10/07/2004US20040198787 Efficient process for the preparation of a factor Xa inhibitor
10/07/2004US20040198782 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration
10/07/2004US20040198739 Prevention reproduction of virus
10/06/2004EP1169312B1 Glucokinase activators
10/05/2004US6800637 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
10/05/2004US6800620 Contacting leukocytes, osteoclasts with an enzyme inhibitors, a 9h-purin-3h-quinazolin-4-one derivatives, treating bone-resorption disorder, antiproliferative agents treating leukemia cells
10/05/2004CA2128956C Tricyclic diazepine vasopressin antagonists
09/2004
09/30/2004WO2004083177A2 Linear chain substituted monocyclic and bicyclic derivatives as factor xa inhibitors
09/30/2004WO2004083176A2 Purification of taxanes and taxane mixtures using polyethyleneimine-bonded resins
09/30/2004WO2004083175A2 Methods for identifying enzyme inhibitors and protein kinases
09/30/2004WO2004083174A2 Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
09/30/2004WO2004083173A2 Ketopiperazine derivatives as bradykinin antagonists
09/30/2004WO2004083172A2 Process for the preparation of 7-amino (p-hydroxyphenylglyclyamido) cephem compounds
09/30/2004WO2004083170A2 Compounds, a process for their preparation and their use as dyes and pigments
09/30/2004WO2004082577A2 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
09/30/2004WO2004046100A3 Release of the self-quenching of fluorescence near silver metallic surfaces
09/30/2004US20040192682 1,5-Dihydro-pyrazolo[4,3-c]pyridazin-6-one derivatives; glycogen synthase kinase-3 (CSK) inhibitors; nervous system, psychological, and neurodegenerative disorders; diabetes, psychiatry, multiple sclerosis (MS), myocardial infarction, reperfusion/ischemia, alopecia, and stroke
09/30/2004US20040192653 P38 inhibitors and methods of use thereof
1 ... 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 ... 105